首页 > 技术支持 > 文献速递

Systems vaccinology and the architecture of human immunity

Nature
Vaccination is one of the greatest triumphs in human history. Traditionally, vaccines were designed to stimulate antibody responses that block infection, but this overlooks the immune system’s complex and multifaceted defence mechanisms. Here we review the current state of the field of systems vaccinology, which has transformed vaccine research by using vaccines as controlled probes of the human immune system and by applying multi-omics and computational approaches to reveal the nature of human immunity. These approaches have identified molecular signatures that predict the magnitude and durability of immune responses and revealed new human biology, including how host genetics, metabolism and the microbiome shape immunity, and demonstrated that host defence emerges from coordinated immune programs spanning baseline immune state, early response dynamics and tissue-level interactions. Rapid advances in artificial intelligence are beginning to accelerate the distillation of knowledge and understanding from vast multi-omics datasets. These developments position systems vaccinology as a powerful framework for rational vaccine design. However, despite its considerable impact on discovery and human immunology, considerable challenges remain in translating these insights into clinical and regulatory practice. Addressing this translational gap will be essential for realizing the full potential of systems vaccinology to deliver safer, more effective vaccines against existing and emerging infectious threats.

Related products

Catalog No. Product Name Description Target
HV212016 Research Grade Belimumab Belimumab (HV212016) is a research-grade recombinant antibody targeting CD257. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns. BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor